

## Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

LOS ANGELES, July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will deliver a presentation at Viruses of Microbes 2024, which is being held July 15-19, 2024, in Cairns, Australia.

Details of the presentation are as follows:

**Title:** **Advancing Bacteriophage Therapy from Discovery to Clinical Trials**

**Session:** Phage Therapy Session 2 – Clinical Application

**Presenter:** Steven Branston, Australia Site Head

**Day:** Thursday, July 18

**Time:** 11:20am-11:40am AEST (9:20pm-9:40pm EDT on Wednesday, July 17)

For more information: <https://www.vom2024.org/>

### **About Armata Pharmaceuticals, Inc.**

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

### **Media Contacts:**

#### **At Armata:**

Pierre Kyme  
Armata Pharmaceuticals, Inc.  
[ir@armatapharma.com](mailto:ir@armatapharma.com)  
310-665-2928

#### **Investor Relations:**

Joyce Allaire  
LifeSci Advisors, LLC  
[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)  
212-915-2569

SOURCE Armata Pharmaceuticals, Inc.

---

<https://investor.armatapharma.com/2024-07-10-Armata-Pharmaceuticals-Announces-Presentation-at-Viruses-of-Microbes-2024>